EU and US could reach trade deal this weekend - Reuters
WILMINGTON, Mass. -On Wednesday, Charles River Laboratories International, Inc. (NYSE:CRL) reported fourth-quarter earnings and revenue that topped analyst estimates, but issued full-year 2025 guidance below expectations.
Charles River’s stock edged up 0.01% in after-hours trading following the earnings release.
The contract research organization posted adjusted earnings per share of $2.66, exceeding the consensus estimate of $2.54. Revenue came in at $1 billion, surpassing analysts’ projections of $985.18 million. However, revenue declined 1.1% YoY from $1.01 billion in Q4 2023.
For the full year 2025, Charles River forecasts adjusted EPS of $9.10-$9.60, below the $9.60 consensus. The company expects revenue to decrease 7.0% to 4.5% on a reported basis and 5.5% to 3.5% organically compared to 2024.
"Throughout 2024, we have launched initiatives to generate more revenue, aggressively reduce costs, and further strengthen our business," said James C. Foster, Chair, President and Chief Executive Officer. "As we move into 2025, we see many of our global biopharmaceutical clients continuing to move forward with their restructuring and pipeline reprioritization activities, which are expected to constrain early-stage spending by many of these clients again in 2025."
The company plans to repurchase approximately $350 million in common stock in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.